Background
Recent studies have identified associations of polymorphisms in several target genes
with antidepressant treatment response of serotonin reuptake inhibitors and a tricyclic
antidepressant. We sought to replicate these associations in a study of a serotonin-norepinephrine
reuptake inhibitor.
Methods
In 250 outpatients with nonpsychotic major depressive disorder, response to treatment
with once-daily duloxetine (60 mg/day) over 6 weeks was examined for associations
with polymorphisms in eight candidate genes previously associated with antidepressant
response using mixed-effect model repeated-measures analysis. Treatment response was
quantified on the basis of changes from baseline using 17-item Hamilton Depression
Rating Scale total scores.
Results
Polymorphisms in PDE1A, PDE1C, PDE6A, PDE11A, ABCB1, GRIK4, SLC6A4, and OPRM1 genes showed no statistically significant associations (uncorrected, two-tailed p > .05) with duloxetine treatment response.
Conclusions
Previously, described associations between polymorphisms in candidate genes and antidepressant
treatment response were not replicated in this study. This result may suggest that
previous associations are specific to serotonin reuptake inhibitors.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Biological PsychiatryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees.J Psychiatr Res. 1998; 32: 255-259
- Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder.World J Biol Psychiatry. 2008; 9: 190-197
- Receptor is associated with response to antidepressant treatment.2008 (Presented at the 7th Annual Pharmacogenetics in Psychiatry Meeting, April 4–5, 2008, New York, NY)
- Sequence analysis of the serotonin transporter and associations with antidepressant response.Biol Psychiatry. 2005; 58: 374-381
- Pharmacogenetics of the serotonin transporter.Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29: 1062-1073
- SLC6A4 variation and citalopram response.Am J Med Genet B Neuropsychiatr Genet. 2009; 150B: 341-351
- Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: A pilot study.Pharmacol Rev. 2008; 58: 344-347
- Association of GRIK4 with outcome of antidepressant treatment in the STAR* D cohort.Am J Psychiatry. 2007; 164: 1181-1188
- Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression.Neuron. 2008; 57: 203-209
- Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response.Proc Natl Acad Sci U S A. 2006; 103: 15124-15129
- Curses—winner's and otherwise—in genetic epidemiology.Epidemiology. 2008; 19: 649-651
- A comparison of initial duloxetine dosing strategies in patients with major depressive disorder.J Clin Psychiatry. 2007; 68: 1921-1930
- Pharmacogenetic studies in depression: A proposal for methodologic guidelines.Pharmacogenomics J. 2008; 8: 90-100
- Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder.Biol Psychiatry. 2009; 65: 785-791
- Automated genotyping using the DNA MassArray technology.Methods Mol Biol. 2002; 187: 179-192
- Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites.J Pharmacol Exp Ther. 1997; 283: 1305-1322
- 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study.J Clin Psychopharmacol. 2003; 23: 563-567
- The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder.Psychopharmacology. 2004; 174: 525-529
- Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment.Biol Psychiatry. 2003; 54: 879-883
Article info
Publication history
Published online: January 28, 2010
Accepted:
December 8,
2009
Received in revised form:
October 28,
2009
Received:
May 23,
2009
Identification
Copyright
© 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
